Actively Recruiting
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
Led by Northwestern University · Updated on 2026-04-13
1000
Participants Needed
6
Research Sites
195 weeks
Total Duration
On this page
Sponsors
N
Northwestern University
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.
CONDITIONS
Official Title
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 30 years or older
- Prior diagnosis of heart failure recorded in electronic health records (any left ventricular ejection fraction) for heart failure group
- No known prior diagnosis of heart failure or use of loop diuretics for non-heart failure group
- No prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml for non-heart failure group if lab tests are available
- Left ventricular ejection fraction 50% or higher measured by echocardiography for HFpEF group
- Signs and symptoms of heart failure, New York Heart Association functional class II-IV, and at least one of the following: elevated BNP or NTproBNP at baseline, prior heart failure hospitalization with elevated natriuretic peptides, elevated pulmonary capillary wedge pressure at rest or during exercise, or elevated H2FPEF or HFA-PEFF score for HFpEF group
- Left ventricular ejection fraction 50% or higher with no prior heart failure diagnosis or diuretic use, and BNP <75 pg/ml or NTproBNP <225 pg/ml at screening for non-HFpEF group
You will not qualify if you...
- Prior known left ventricular ejection fraction less than 50% for non-heart failure group
- Prior history of solid organ transplantation
- Prior history of mechanical circulatory support
- Prior history of non-cardiac cirrhosis
- Inability to provide written consent
- Life expectancy less than 1 year
- Primary cardiomyopathy or pulmonary arterial hypertension
- Prior known left ventricular ejection fraction less than 40%, except in acute tachycardia episodes
- Significant valvular heart disease including moderate or greater stenosis or regurgitation in specified valves
- Planned cardiac surgery or intervention in the next 3 months
- Alternative primary cause for symptoms in HFpEF participants
- Recent cardiac surgery, acute coronary syndrome, or stroke within 6 months
- Known symptomatic epicardial coronary artery disease not revascularized
- Non-elective hospitalization within 2 weeks
- Prior history of chronic infection unless treated and inactive
- Estimated glomerular filtration rate less than 20 ml/min/1.73m2 or dialysis
- Conditions preventing participation or adherence
- Current acute decompensated heart failure
- Currently pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
University of California Davis
Sacramento, California, United States, 95817
Actively Recruiting
2
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
3
Mass General Brigham
Boston, Massachusetts, United States, 02114
Not Yet Recruiting
4
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
5
Wake Forest University
Winston-Salem, North Carolina, United States, 27157
Not Yet Recruiting
6
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
L
Laura Alagna
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here